ARTHROPLASTY
TXA effective in reducing blood loss in mini-invasive TKA with postoperative rivaroxaban
J Arthroplasty. 2017 Mar;32(3):801-806200 patients scheduled for minimally invasive total knee arthroplasty and thromboprophylaxis with rivaroxaban were randomized to either intravenous tranexamic acid or placebo. Patients were assessed for blood loss, transfusion rate, hemoglobin levels, rates of ecchymosis, wound hematoma, and deep infection. Total blood loss was significantly lower in the TXA group compared to placebo, while no significant difference was observed in postoperative drain volume. Transfusion rate was significantly lower in the TXA group compared to the placebo group, as were the incidences of ecchymosis and hematoma.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
